Clinician guide

Hyperlipidemia

A practical primary care reference.

This clinician mode is designed for quick orientation and deeper review. It preserves uncertainty and patient-specific judgment while keeping traditional medicine and lifestyle medicine together.

Patient mode Clinician mode

Key takeaways

LDL-C and ASCVD risk have a causal, dose-dependent, log-linear relationship; both magnitude and duration of exposure matter.

Use the 2026 ACC/AHA Calculate risk → Personalize → Reclassify/Reassess model, including PREVENT-ASCVD, risk enhancers, and CAC when treatment decisions remain uncertain.

Evaluate secondary causes, familial hypercholesterolemia, comorbidities, medications, substances, and social barriers.

Measure Lp(a) at least once in all adults; use apoB selectively when residual risk is suspected.

Statins are first-line LDL-lowering therapy; add-on therapy depends on risk, achieved response, tolerability, safety, and context.

Lifestyle medicine is foundational across risk categories and should continue before, alongside, and throughout pharmacotherapy.

Visual overview

A primary care pathway from lipid pattern to durable risk reduction.

Confirm

Characterize the lipid pattern and exclude important secondary causes.

Risk

Assess PREVENT-ASCVD risk, enhancers, familial disease, comorbidities, and context.

Treat

Integrate pharmacotherapy and lifestyle medicine according to risk and safety.

Revise

Reassess lipids, response, tolerability, adherence, barriers, and changing risk.

Clinician reference

Structured for use.

A practical reference for classification, diagnosis, evaluation, management, monitoring, special populations, patient communication, and areas where clinical judgment remains necessary.

Hyperlipidemia classification by lipid pattern.
Classification	Pattern	Notes
Isolated hypercholesterolemia	Elevated LDL-C	May be primary, secondary, or polygenic.
Isolated hypertriglyceridemia	Elevated triglycerides	Assess metabolic, alcohol, medication, renal, thyroid, and genetic contributors.
Mixed hyperlipidemia	Elevated LDL-C and triglycerides	Combined risk and treatment considerations apply.
Isolated low HDL-C	Low HDL-C	Falls within the broader definition of dyslipidemia.
Atherogenic dyslipidemia	High triglycerides, low HDL-C, small dense LDL	Common with insulin resistance and type 2 diabetes.

Clinical summary+

Hyperlipidemia is a major modifiable risk factor for atherosclerotic cardiovascular disease. It is usually asymptomatic and is identified through lipid testing. The relationship between LDL-C exposure and ASCVD risk is causal, dose-dependent, and log-linear.

Management requires characterization of the lipid abnormality, global cardiovascular risk assessment, evaluation for familial and secondary causes, lifestyle medicine, pharmacotherapy when appropriate, monitoring, and longitudinal reassessment.

Physiology and pathophysiology+

Lipoproteins coordinate cholesterol and triglyceride transport. Chylomicrons carry dietary triglycerides; VLDL carries endogenous triglycerides and is converted through IDL to LDL; HDL participates in reverse cholesterol transport; hepatic LDL receptors are central to LDL clearance.

LDL retention

ApoB-containing lipoproteins enter and are retained in the arterial intima, undergo modification, and promote monocyte recruitment and foam-cell formation.

Plaque progression

Inflammation, smooth-muscle migration, matrix deposition, and neovascularization contribute to plaque progression and vulnerability.

Triglyceride-rich remnants

TRLs and their remnants contribute independently to ASCVD risk.

Lp(a)

Lp(a) promotes atherogenesis, inflammation, and thrombosis through apolipoprotein(a) and associated oxidized phospholipids.

Epidemiology and disparities+

Approximately 25% of U.S. adults have LDL-C ≥130 mg/dL, and more than 100 million Americans have elevated total cholesterol. Global meta-analysis estimates hypertriglyceridemia at 28.8%, hypercholesterolemia at 24.1%, low HDL-C at 38.4%, and elevated LDL-C at 18.9%.

Familial hypercholesterolemia

HeFH affects approximately 1 in 250–300 people; HoFH affects approximately 1 in 300,000. FH remains significantly underdiagnosed.

Young adults

Lipid screening in adults ages 20–45 is reported at 50%, despite roughly half meeting dyslipidemia criteria.

Health equity

Structural racism, socioeconomic disadvantage, food access, health literacy, and limited healthcare access contribute to inequity.

Natural history, complications, and prognosis+

Cumulative exposure to elevated LDL-C drives progression from early fatty streaks to fibrous and complex atherosclerotic plaque. Clinical risk rises with the magnitude and duration of exposure.

ASCVD

Complications include coronary artery disease, ischemic stroke or TIA, peripheral artery disease, aortic and carotid atherosclerosis, ischemic cardiomyopathy, and cardiovascular death.

Severe hypertriglyceridemia

Triglycerides ≥1,000 mg/dL are associated with acute pancreatitis.

Familial disease

Untreated HeFH carries substantial premature coronary risk; untreated HoFH can cause severe ASCVD in childhood or adolescence.

Treatment effect

Statin therapy reduces major vascular events by approximately 22% per 1.0 mmol/L LDL-C reduction across risk categories; benefit is proportional to absolute reduction and treatment duration.

Diagnosis+

There is no single universal diagnostic threshold. Interpret the lipid panel in the context of absolute cardiovascular risk, lipid pattern, family history, comorbidities, and secondary causes.

Finding	Clinical significance
LDL-C ≥190 mg/dL	Severe hypercholesterolemia; evaluate for familial hypercholesterolemia.
Triglycerides ≥500 mg/dL	Severe hypertriglyceridemia.
Triglycerides ≥1,000 mg/dL	Associated with acute pancreatitis.
Lp(a) ≥125 nmol/L or 50 mg/dL	Risk-enhancing level.
Lp(a) ≥250 nmol/L or 100 mg/dL	Associated with at least two-fold higher risk.

Evaluation+

Use the 2026 ACC/AHA CPR model: Calculate risk → Personalize → Reclassify/Reassess.

History

Personal ASCVD history, premature ASCVD or severe hypercholesterolemia family history, diet, activity, tobacco, alcohol, medications, adherence, adverse effects, comorbidities, reproductive history, sleep, stress, social isolation, and socioeconomic context.

Physical examination

Blood pressure, BMI, waist circumference, xanthelasma, corneal arcus, xanthomas, vascular findings, thyroid findings, hepatosplenomegaly, and epigastric tenderness when relevant. The examination is normal in most patients.

Routine tests

Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, and tests for secondary causes such as TSH, glucose or HbA1c, renal function, urinalysis, and hepatic function as indicated.

Additional testing

Lp(a) at least once in all adults; apoB when selected; genetic testing for suspected FH; CAC for selected uncertain decisions; advanced lipid subfraction testing is not routinely recommended.

Nonfasting testing is acceptable for most screening; fasting is preferred when triglyceride assessment is needed, when triglycerides are above 400 mg/dL, or for baseline assessment.

Differential diagnosis+

primary genetic dyslipidemias, including FH, familial combined hyperlipidemia, familial hypertriglyceridemia, FCS, type III hyperlipoproteinemia, and polygenic hypercholesterolemia
hypothyroidism, nephrotic syndrome, chronic kidney disease, obstructive liver disease, diabetes, obesity, and metabolic syndrome
pregnancy, anorexia nervosa, Cushing syndrome, lipodystrophy, glycogen storage disease, polycystic ovary syndrome, and autoimmune disease
medication-related dyslipidemia from thiazides, beta-blockers, glucocorticoids, oral estrogens, atypical antipsychotics, HIV protease inhibitors, isotretinoin, cyclosporine, and other agents
alcohol- and substance-related lipid abnormalities

Management+

Management combines lifestyle medicine and lipid-lowering therapy according to cardiovascular risk, lipid pattern, comorbidities, safety, feasibility, and patient context.

Clinical situation	Management consideration
LDL-C ≥190 mg/dL	Evaluate for FH and initiate risk-focused LDL-lowering therapy.
Diabetes, age 40–75	Moderate- or high-intensity statin therapy is recommended.
CKD stage 3 or 4	Statin therapy is indicated regardless of LDL-C level.
HIV	Statin therapy is recommended with attention to antiretroviral drug interactions.
Uncertain primary-prevention decision	Consider risk enhancers and CAC scoring in eligible adults.
Triglycerides ≥500 mg/dL	Prioritize triglyceride lowering and pancreatitis prevention.

Medications+

Statins are first-line therapy. Ezetimibe, PCSK9 monoclonal antibodies, inclisiran, bempedoic acid, and bile acid sequestrants may be used in selected LDL-lowering strategies. Icosapent ethyl, fibrates, and prescription omega-3 fatty acids have indication-specific roles in triglyceride management. Niacin is no longer routinely recommended.

The Treatment section below summarizes how pharmacotherapy fits within the Contrada two-pillar approach.

Lifestyle medicine+

Lifestyle optimization is foundational across all risk categories and should be initiated before, alongside, and continued throughout pharmacotherapy. Nutrition, physical activity, sleep, stress, social connection, and avoidance of risky substances all matter to lipid management and cardiovascular risk.

The Treatment section below summarizes the major lifestyle domains and how they are integrated with traditional medical management.

Monitoring and follow-up+

Repeat a lipid profile 4–12 weeks after initiating or adjusting lipid-lowering therapy. Reassess every 6–12 months thereafter; every 12 months is appropriate for stable patients with no therapy changes and stable lipid levels.

Assess percentage LDL-C reduction and absolute LDL-C and non-HDL-C goals, adherence, tolerability, lifestyle factors, secondary causes, comorbidities, drug interactions, and barriers before intensifying therapy. Check hepatic transaminases at baseline and thereafter only when clinically indicated. CK is not recommended routinely. Monitor renal function with fibrates or CKD and glycemia periodically with high-intensity statins.

Special populations+

Children and adolescents

Universal lipid screening is recommended at ages 9–11 and 17–21, with earlier targeted screening for premature ASCVD or FH family history. Lifestyle treatment is first-line; selected children with HeFH require statin therapy.

Pregnancy and lactation

Most patients should discontinue statins before pregnancy or when pregnancy is discovered. Selected patients with FH or clinical ASCVD require individualized benefit-risk discussion. Bile acid sequestrants are not systemically absorbed; other agents have pregnancy-specific limitations.

Older adults

Primary-prevention evidence beyond age 75 is limited. Balance ASCVD prevention with frailty, multimorbidity, polypharmacy, functional status, life expectancy, and time to benefit.

Diabetes

Atherogenic dyslipidemia is common; moderate- or high-intensity statin therapy is recommended for adults ages 40–75.

Chronic kidney disease

Statins are indicated in stages 3–4, but initiation is not recommended in dialysis patients. Monitor renal function and drug selection.

HIV

Review drug interactions; avoid simvastatin and lovastatin with protease inhibitors, and consider pitavastatin when appropriate.

Patient communication+

Lipid numbers matter because exposure affects risk over time, even when the patient feels well.
A lipid value should be interpreted within the whole cardiovascular-risk picture.
Medication and lifestyle medicine are complementary, not competing approaches.
Treatment intensity should match risk, safety, feasibility, and the patient's goals and circumstances.
If the plan is not feasible in daily life, identify the barrier and revise the plan.

Pearls and pitfalls+

Pearls

Cumulative LDL-C exposure matters; earlier risk recognition can change lifetime risk.
Evaluate LDL-C ≥190 mg/dL for familial hypercholesterolemia.
Measure Lp(a) at least once in all adults.
Use CAC selectively to resolve treatment uncertainty, not as routine screening for every patient.
Reassess adherence, secondary causes, lifestyle factors, and drug interactions before escalating therapy.

Pitfalls

Treating a lipid number without global risk assessment.
Missing severe hypertriglyceridemia and pancreatitis risk.
Failing to document myalgia timing, severity, and prior rechallenge attempts when evaluating statin intolerance.
Using over-the-counter fish oil or red yeast rice as equivalent substitutes for indicated prescription therapy.
Treating medication as a substitute for lifestyle and social assessment.

Guideline notes and uncertainty+

The primary source is the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline and its guideline-at-a-glance summary. The Master file also incorporates major guideline, review, scientific-statement, consensus, and trial evidence.

Important areas of uncertainty include primary prevention in adults older than 75, the clinical-outcome role of Lp(a)-lowering therapies, the future role of polygenic risk scores, optimal use of imaging surrogates, long-term outcomes of comprehensive lifestyle interventions, and cannabis-related cardiovascular risk.

Evidence gaps and future directions+

Several areas require continued review as evidence develops.

Emerging LDL therapies

Oral and long-acting PCSK9 approaches, CETP inhibition, and combination strategies remain active areas of study.

Triglyceride and remnant pathways

ANGPTL3 and apoC-III targeting may expand treatment for severe and familial disorders.

Lp(a)

Pelacarsen, olpasiran, lepodisiran, and muvalaplin lower Lp(a), but outcomes evidence and treatment thresholds remain under study.

Gene-based therapies

PCSK9, ANGPTL3, apoC-III, and Lp(a) editing or silencing approaches are early or investigational.

Implementation

Adherence, pharmacist-led care, shared decision-making, digital tools, health equity, and scalable lifestyle support remain unresolved care-delivery challenges.

Treatment

Two pillars, one clinical plan.

In clinician mode, the Contrada approach keeps lipid-lowering therapy and lifestyle medicine together. The balance is determined by lipid pattern, cardiovascular risk, comorbidities, safety, feasibility, patient context, and longitudinal follow-up.

Traditional medicine management

Characterize, risk-stratify, lower exposure, monitor.

Diagnosis

Characterize LDL-C, triglycerides, HDL-C, and non-HDL-C; identify severe or familial patterns and important secondary causes.

Risk and evaluation

Use PREVENT-ASCVD, risk enhancers, Lp(a), apoB when selected, and CAC when eligible patients remain uncertain about treatment.

Pharmacotherapy

Use statins as first-line LDL-lowering therapy. Add ezetimibe, PCSK9 monoclonal antibodies, inclisiran, bempedoic acid, or other therapy according to risk, response, indication, and tolerability. Treat severe hypertriglyceridemia with pancreatitis prevention in mind.

Treatment selection

Account for established ASCVD, diabetes, CKD, HIV, FH, pregnancy, older age, drug interactions, adverse effects, cost, adherence, and patient preferences.

Monitoring

Recheck lipids in 4–12 weeks after initiation or dose adjustment, then every 6–12 months; monitor safety according to the agent and clinical context.

Lifestyle medicine management

Make risk reduction feasible in daily life.

Nutrition

Emphasize replacement of saturated fat with unsaturated fat, soluble fiber, plant protein, Mediterranean or other evidence-based patterns, and reduced processed carbohydrates and added sugars when triglycerides are elevated. Severe hypertriglyceridemia requires specialist-guided fat restriction.

Movement

Encourage at least 150 minutes/week of moderate activity or 75–150 minutes/week of vigorous activity, resistance training at least two days/week, and less sedentary time, adapted to ASCVD status and patient context.

Sleep and stress

Assess sleep duration and quality, insomnia, OSA, chronic stress, depression, and anxiety as part of cardiovascular risk and adherence care.

Social and substance factors

Assess food access, affordability, transportation, health literacy, social connection, tobacco, alcohol, cannabis, medications, and supplements.

Secondary contributors

Address diabetes, insulin resistance, obesity, hypothyroidism, kidney or liver disease, nephrotic syndrome, medication effects, and other modifiable contributors.

References and review

This clinician guide is derived from the hyperlipidemia Knowledge Database source documents. Full citations and source-tracking notes are maintained in the internal references file. This Academy page has been reviewed according to Contrada Academy standards for educational use.